The Danish equity market, led by the OMX Copenhagen 25, has demonstrated resilience in the current interest rate environment, driven primarily by the outsised weight of Novo Nordisk A/S and the pharmaceutical sector. However, rotation dynamics within the index and diverging performances across Nordic exchanges present both challenges and opportunities for equity research consumers.
Our equity research covers companies listed on Nasdaq Copenhagen, Stockholm Stock Exchange, Oslo Bors and Helsinki Stock Exchange, with selective coverage of DAX, FTSE 100 and US large-cap equities where relevant to Nordic investors.
| Company | Exchange | Sector | P/E (TTM) | Rating | Last Updated |
|---|---|---|---|---|---|
| Novo Nordisk A/S | Nasdaq CPH | Healthcare | 32.4x | Neutral | June 2024 |
| A.P. Møller-Mærsk A/S | Nasdaq CPH | Industrials | 4.1x | Overweight | June 2024 |
| Vestas Wind Systems | Nasdaq CPH | Energy | 28.7x | Accumulate | May 2024 |
| DSV A/S | Nasdaq CPH | Logistics | 19.3x | Overweight | June 2024 |
| Ørsted A/S | Nasdaq CPH | Utilities | N/M | Reduce | May 2024 |
| Genmab A/S | Nasdaq CPH | Biotech | 18.6x | Accumulate | June 2024 |
DCF models, comparables analysis (EV/EBITDA, P/E, P/S), NAV assessments for asset-heavy companies and sum-of-parts valuations for conglomerates.
Accrual ratio analysis, free cash flow conversion, non-recurring item adjustments and earnings persistence scoring based on historical revision patterns.
Beta calculation, volatility profiling, Altman Z-score, leverage ratios and sector-specific risk factors including regulatory and competitive dynamics.
We use cookies to enhance your experience, analyse site traffic, and support our analytical services. By clicking "Accept All", you consent to our use of cookies as described in our Cookie Policy. You may decline non-essential cookies.